AJP - Endo Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 291: E1317-E1324, 2006. First published July 18, 2006; doi:10.1152/ajpendo.00082.2006
0193-1849/06 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/6/E1317    most recent
00082.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (36)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meier, J. J.
Right arrow Articles by Butler, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meier, J. J.
Right arrow Articles by Butler, P. C.

Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP

Juris J. Meier,1 Rakez Kayed,2 Chia-Yu Lin,1 Tatyana Gurlo,1 Leena Haataja,1 Sajith Jayasinghe,3 Ralf Langen,3 Charles G. Glabe,2 and Peter C. Butler1

1Larry Hillblom Islet Research Center, University of California Los Angeles David Geffen School of Medicine, Los Angeles; 2Department of Molecular Biology and Biochemistry, University of California, Irvine; and 3Department of Biochemistry and Molecular Biology, Zilkha Neurogenetic Institute, University of Southern California, Los Angeles, California

Submitted 17 February 2006 ; accepted in final form 17 July 2006

Type 2 diabetes mellitus (T2DM) is characterized by an ~60% deficit in beta-cell mass, increased beta-cell apoptosis, and islet amyloid derived from islet amyloid polypeptide (IAPP). Human IAPP (hIAPP) forms oligomers, leading to either amyloid fibrils or toxic oligomers in an aqueous solution in vitro. Either application of hIAPP on or overexpression of hIAPP in cells induces apoptosis. It remains controversial whether the fibrils or smaller toxic oligomers induce beta-cell apoptosis. Rifampicin prevents hIAPP amyloid fibril formation and has been proposed as a potential target for prevention of T2DM. We examined the actions of rifampicin on hIAPP amyloid fibril and toxic oligomer formation as well as its ability to protect beta-cells from either application of hIAPP or endogenous overexpression of hIAPP (transgenic rats and adenovirus-transduced beta-cells). We report that rifampicin (Acocella G. Clin Pharmacokinet 3: 108–127, 1978) prevents hIAPP fibril formation, but not formation of toxic hIAPP oligomers (Bates G. Lancet 361: 1642–1644, 2003), and does not protect beta-cells from apoptosis induced by either overexpression or application of hIAPP. These data emphasize that toxic hIAPP oligomers, rather than hIAPP fibrils, initiate beta-cell apoptosis and that screening tools to identify inhibitors of amyloid fibril formation are likely to be less useful than those that identify inhibitors of toxic oligomer formation. Finally, rifampicin and related molecules do not appear to be useful as candidates for prevention of T2DM.

islet amyloid polypeptide; human islet amyloid polypeptide; rifampicin



Address for reprint requests and other correspondence: P. C. Butler, Larry Hillblom Islet Research Center, UCLA David Geffen School of Medicine, 24-130 Warren Hall, 900 Veteran Ave., Los Angeles, CA 90095–7073 (e-mail: pbutler{at}mednet.ucla.edu)




This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
T. Hartley, J. Brumell, and A. Volchuk
Emerging roles for the ubiquitin-proteasome system and autophagy in pancreatic {beta}-cells
Am J Physiol Endocrinol Metab, January 1, 2009; 296(1): E1 - E10.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
S. Zhang, H. Liu, H. Yu, and G. J.S. Cooper
Fas-Associated Death Receptor Signaling Evoked by Human Amylin in Islet {beta}-Cells
Diabetes, February 1, 2008; 57(2): 348 - 356.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
C.-j. Huang, L. Haataja, T. Gurlo, A. E. Butler, X. Wu, W. C. Soeller, and P. C. Butler
Induction of endoplasmic reticulum stress-induced -cell apoptosis and accumulation of polyubiquitinated proteins by human islet amyloid polypeptide
Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1656 - E1662.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
R. L. Hull, S. Zraika, J. Udayasankar, R. Kisilevsky, W. A. Szarek, T. N. Wight, and S. E. Kahn
Inhibition of glycosaminoglycan synthesis and protein glycosylation with WAS-406 and azaserine result in reduced islet amyloid formation in vitro
Am J Physiol Cell Physiol, November 1, 2007; 293(5): C1586 - C1593.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
S. Casas, R. Gomis, F. M. Gribble, J. Altirriba, S. Knuutila, and A. Novials
Impairment of the Ubiquitin-Proteasome Pathway Is a Downstream Endoplasmic Reticulum Stress Response Induced by Extracellular Human Islet Amyloid Polypeptide and Contributes to Pancreatic {beta}-Cell Apoptosis
Diabetes, September 1, 2007; 56(9): 2284 - 2294.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.